14.10.2016
Summary
Objectives
The objective of this study is to investigate whether PsA comorbidities, assessed by use of the CCI, are associated with disease activity, treatment response and treatment adherence in patients with PsA treated with their first TNFi. Furthermore, we will assess whether depression and/or anxiety have an influence on the treatment effect and adherence.
Investigators
Christine Ballegaard1,2, Pil Højgaard1,2, Lene Dreyer1,2, René Cordtz1,2, Tanja Schjødt Jørgensen1,
Marie Skougaard1, Simon Tarp1, Lars Erik Kristensen1
